WVP
VNDA icon

Worth Venture Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Worth Venture Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-89,124
Closed -$1.17M – 132
2020
Q4 		$1.17M Buy
89,124
+6,335
+8% +$76.3K 0.93% 33
2020
Q3 		$799K Buy
+82,789
New +$885K 0.66% 37

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Worth Venture Partners's VNDA Position: Q1 2021 in Review

Worth Venture Partners sold out of Vanda Pharmaceuticals (VNDA) in Q1 2021, closing a stake of 89,124 shares — an estimated $1.17M sold.

Worth Venture Partners first reported a position in VNDA in Q3 2020 and held it in 2 quarters. The position peaked at $1.17M in Q4 2020. 189 funds tracked by Wall St. Rank hold VNDA as of Q1 2021.

  • Worth Venture Partners reported no remaining Vanda Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Worth Venture Partners sold 89,124 Vanda Pharmaceuticals shares in Q1 2021, an estimated $1.17M.
  • Worth Venture Partners first reported a position in Vanda Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Worth Venture Partners's Vanda Pharmaceuticals position peaked at $1.17M in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2021.

Based on Worth Venture Partners's 13F filing for Q1 2021, filed 17 May 2021.